137 related articles for article (PubMed ID: 31091718)
1. A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An
Wang H; Cui J; Yang C; Rosenblum JS; Zhang Q; Song Q; Pang Y; Fang F; Sun M; Dmitriev P; Gilbert MR; Eisenhofer G; Pacak K; Zhuang Z
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31091718
[TBL] [Abstract][Full Text] [Related]
2. Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia.
Yang C; Hong CS; Prchal JT; Balint MT; Pacak K; Zhuang Z
Hum Genome Var; 2015; 2():15053. PubMed ID: 27081557
[TBL] [Abstract][Full Text] [Related]
3. Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome.
Dmitriev PM; Wang H; Rosenblum JS; Prodanov T; Cui J; Pappo AS; Gilbert MR; Lutty GA; Chan CC; Chew EY; Pacak K; Zhuang Z
JAMA Ophthalmol; 2020 Feb; 138(2):148-155. PubMed ID: 31876943
[TBL] [Abstract][Full Text] [Related]
4. Novel mutations in EPO-R and oxygen-dependent degradation (ODD) domain of EPAS1 genes-a causative reason for Congenital Erythrocytosis.
Echambadi Loganathan S; Kattaru S; Chandrasekhar C; Vengamma B; Sarma PVGK
Eur J Med Genet; 2022 Jun; 65(6):104493. PubMed ID: 35395428
[TBL] [Abstract][Full Text] [Related]
5. Developmental vascular malformations in EPAS1 gain-of-function syndrome.
Rosenblum JS; Wang H; Dmitriev PM; Cappadona AJ; Mastorakos P; Xu C; Jha A; Edwards N; Donahue DR; Munasinghe J; Nazari MA; Knutsen RH; Rosenblum BR; Smirniotopoulos JG; Pappo A; Spetzler RF; Vortmeyer A; Gilbert MR; McGavern DB; Chew E; Kozel BA; Heiss JD; Zhuang Z; Pacak K
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33497361
[TBL] [Abstract][Full Text] [Related]
6. Neuraxial dysraphism in
Rosenblum JS; Cappadona AJ; Argersinger DP; Pang Y; Wang H; Nazari MA; Munasinghe JP; Donahue DR; Jha A; Smirniotopoulos JG; Miettinen MM; Knutsen RH; Kozel BA; Zhuang Z; Pacak K; Heiss JD
Neurol Genet; 2020 Jun; 6(3):e414. PubMed ID: 32337341
[TBL] [Abstract][Full Text] [Related]
7. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
[TBL] [Abstract][Full Text] [Related]
8. New syndrome of paraganglioma and somatostatinoma associated with polycythemia.
Pacak K; Jochmanova I; Prodanov T; Yang C; Merino MJ; Fojo T; Prchal JT; Tischler AS; Lechan RM; Zhuang Z
J Clin Oncol; 2013 May; 31(13):1690-8. PubMed ID: 23509317
[TBL] [Abstract][Full Text] [Related]
9. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
10. Chiari Malformation Type 1 in
Rosenblum JS; Maggio D; Pang Y; Nazari MA; Gonzales MK; Lechan RM; Smirniotopoulos JG; Zhuang Z; Pacak K; Heiss JD
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185588
[TBL] [Abstract][Full Text] [Related]
11. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
12. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male.
Toyoda H; Hirayama J; Sugimoto Y; Uchida K; Ohishi K; Hirayama M; Komada Y
Pediatrics; 2014 Jun; 133(6):e1787-91. PubMed ID: 24819565
[TBL] [Abstract][Full Text] [Related]
13. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.
Pang Y; Gupta G; Jha A; Yue X; Wang H; Huynh TT; Li A; Li L; Baker E; Chew E; Feelders RA; Korpershoek E; Zhuang Z; Yang C; Pacak K
Cancer; 2019 Apr; 125(8):1258-1266. PubMed ID: 30644531
[TBL] [Abstract][Full Text] [Related]
14. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
[TBL] [Abstract][Full Text] [Related]
15. Case Report: A novel
Yang H; Chen Y; Liu K; Zhao L
Front Endocrinol (Lausanne); 2023; 14():1180091. PubMed ID: 37576964
[TBL] [Abstract][Full Text] [Related]
16. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
[TBL] [Abstract][Full Text] [Related]
17. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
18. Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor.
Divoky V; Song J; Horvathova M; Kralova B; Votavova H; Prchal JT; Yoon D
J Mol Med (Berl); 2016 May; 94(5):597-608. PubMed ID: 26706855
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.
Därr R; Nambuba J; Del Rivero J; Janssen I; Merino M; Todorovic M; Balint B; Jochmanova I; Prchal JT; Lechan RM; Tischler AS; Popovic V; Miljic D; Adams KT; Prall FR; Ling A; Golomb MR; Ferguson M; Nilubol N; Chen CC; Chew E; Taïeb D; Stratakis CA; Fojo T; Yang C; Kebebew E; Zhuang Z; Pacak K
Endocr Relat Cancer; 2016 Dec; 23(12):899-908. PubMed ID: 27679736
[TBL] [Abstract][Full Text] [Related]
20. EPAS-1-related pheochromocytoma/paraganglioma: How common and how aggressive?
Alzahrani AS; Alswailem M; Buffet A; Alghamdi B; Alobaid L; Alsagheir O; Al-Hindi H; Pacak K
Endocr Relat Cancer; 2024 May; ():. PubMed ID: 38767322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
